Dr. Vidal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7945 Wolf River Blvd
Germantown, TN 38138Phone+1 901-683-0055Fax+1 901-685-2969
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2010 - 2013
Tulane University School of MedicineClass of 2008
Certifications & Licensure
TN State Medical License 2014 - 2026
CA State Medical License 2010 - 2025
MS State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Start of enrollment: 2015 Aug 01
- Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast Start of enrollment: 2019 Jun 21
Publications & Presentations
PubMed
- 209 citationsThe ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperoneChristopher Williams, June G. Allison, Gregory A. Vidal, Matthew E. Burow, Barbara S. Beckman
The Journal of Cell Biology. 2004-11-08 - 29 citations"Nobody Will Tell You. You've Got to Ask!": An Examination of Patient-provider Communication Needs and Preferences among Black and White Women with Early-stage Breast ...Janeane N. Anderson, J. Carolyn Graff, Rebecca A. Krukowski, Lee S. Schwartzberg, Gregory A. Vidal
Health Communication. 2021-09-19 - 58 citationsUse of a Web-based App to Improve Breast Cancer Symptom Management and Adherence for Aromatase Inhibitors: A Randomized Controlled Feasibility TrialIlana Graetz, Caitlin N. McKillop, Edward J. Stepanski, Gregory A. Vidal, Janeane N. Anderson
Journal of Cancer Survivorship. 2018-02-28
Press Mentions
Is the FDA Making the Right Moves on Clinical Trials?October 21st, 2024- World-Renowned Cancer Experts to Speak at the West Oncology Conference in MemphisDecember 26th, 2022
- West Cancer Center, Memphis Breast Cancer Consortium and Rabble Health Announce New InitiativeJune 29th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
